A long and volatile era finally came to an end last week for Dendreon Corp as the US Food & Drug Administration granted approval for Provenge, the company's immunotherapeutic treatment for men with advanced prostate cancer.
The end of this era, however, marks the dawn of a new one. Doctors and patie...
